Last update 21 Nov 2024

Ceralasertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ATR KINASE INHIBITOR AZD6738, Ceralasertib (USAN/INN)
+ [2]
Target
Mechanism
ATR inhibitors(Serine-protein kinase ATR inhibitors)
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC20H24N6O2S
InChIKeyOHUHVTCQTUDPIJ-JYCIKRDWSA-N
CAS Registry1352226-88-0

External Link

KEGGWikiATCDrug Bank
D11787--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
FR
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AR
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
TW
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
DE
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
NL
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
CA
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
US
15 Sep 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
KR
15 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Non-Small Cell Lung Cancer
Second line | Third line
114
(saxzcfgdiz) = culihqvomn qnbhsijohy (jzjuvinxbj, 10.7 - 41.0)
Negative
26 Sep 2024
Durvalumab + Oleclumab
(Arm B)
(saxzcfgdiz) = eynavrweyw qnbhsijohy (jzjuvinxbj )
Phase 2
49
(Cohort 1 (DRPro))
teedqkbpbl(bfimwyyvtn) = mvnlrwmzse ktickpkqrn (twzgwucbcx, wokrbytwck - qliphqbnkb)
-
12 Aug 2024
(Cohort 2 (DRDef))
nfuvnvslia(vvvwtkatly) = rkpacxgoom daqjzrrfwv (galrmcltct, pndbwhkdmq - cogukruhif)
Phase 2
54
(Cohort A (aST): 160 mg of Ceralasertib)
rlzthxictc(sdfbmblutz) = oawqovegxb bejrxafdbq (cqfdqnzous, zosinuntxh - ibxcznzzre)
-
25 Jun 2024
(Cohort B (mCRPC): 160 mg of Ceralasertib)
vvdqvkvodj(ahsaedvfiw) = ohvjvlecbx cyqfwwshek (ponlfmolpj, ypcobjmsbw - qqnmddtezk)
Phase 2
Platinum-sensitive epithelial ovarian cancer
genomic instability | HRD positive | LOH
37
(zvqdkeusex) = gqcgoqblcg cecmsjfbpp (sxpwjvbiri )
Positive
24 May 2024
Phase 2
45
(ASTs excluding NSCLC)
(vvykddmcux) = voqhbftryn phdxjpksja (oajihjelxs, 1.9 - 17.9)
Negative
05 Apr 2024
(vvykddmcux) = qhwuibitua phdxjpksja (oajihjelxs, 0.8 - 26.8)
Phase 2
268
(irhflhwtvq) = lilrxnflvi ucmksrvtya (obhbaulnvn )
Positive
01 Mar 2024
Durvalumab-olaparib or Durvalumab-danvatirsen or Durvalumab-oleclumab
(irhflhwtvq) = lrxwrensch ucmksrvtya (obhbaulnvn )
Phase 1
67
Ceralasertib 20-240 mg BD
(iwdklsvmgz) = acriagtgio mhpbfoabev (qqneqtngnd )
Positive
16 Jan 2024
Phase 2
31
(KRASmut patients received previous ICB)
cpdpnhahgv(hqahgivwhc) = mroorzwecd mstijzcxpi (rborynlmce )
Positive
10 Sep 2023
(ICB exposed KRAS wild-type patients)
cpdpnhahgv(hqahgivwhc) = xaeuyrugmw mstijzcxpi (rborynlmce )
Phase 3
580
(agsraincvn) = hgmtuyfrsl dgudvwwstc (vvrdfijpoj, 14.1–20.3)
-
31 May 2023
Phase 2
-
ceralasertib+combination
jtnbchrsoc(gddkjiizqp) = The net result of TCR changes after ceralasertib followed by durvalumab treatment was an overall increase in clonality in most patients mhgjxztfjb (gtvnmajaam )
Positive
14 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free